Colorectal Cancer

>

Latest News

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.
A2B530 Earns FDA Orphan Drug Designation in CEA+ Colorectal Cancer

March 6th 2024

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.
ctDNA-Based Negative Hyperselection May Guide Treatment Selection in mCRC

March 3rd 2024

The FDA has set a Prescription Drug User Fee Act date of June 21, 2024 for adagrasib plus cetuximab as a treatment for patients with previously treated KRAS G12C-mutated colorectal cancer.
FDA Grants Priority Review to Adagrasib Combo in KRAS G12C+ Advanced CRC

February 21st 2024

Investigators of the AMPLIFY-201 trial hypothesized that ELI-002 2P may induce the expansion of functional tumor-directed KRAS-mutated specific T cells following tumor resection.
Cancer Vaccine Shows Efficacy and Safety Potential in PDAC and CRC

February 13th 2024

Results from part 3 of the phase 2a CORIST trial found that combining SCO-101 with chemotherapy improved the progression-free survival and clinical benefit rate in patients with metastatic colorectal cancer.
Novel Drug Shows Increased Efficacy in Small Metastatic CRC Population

February 6th 2024

More News